EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSMMDG00005014719
Gene Symbol: BDKRB2
1 Cross references
155 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSMMDG00005023979
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSMMDG00005010856
Gene Symbol: CACNA1DA
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSMMDG00005019540
Gene Symbol: CACNA1FB
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, A

Ensembl ID : ENSMMDG00005000576
Gene Symbol: CACNA1SA
1 Cross references
195 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSMMDG00005001533
Gene Symbol: CACNA1SB
1 Cross references
199 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSMMDG00005004588
Gene Symbol: CACNA1BA
1 Cross references
219 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSMMDG00005000641
Gene Symbol: CACNA1AB
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSMMDG00005020111
Gene Symbol: CACNA2D1A
1 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSMMDG00005003327
Gene Symbol: CACNA2D2A
1 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSMMDG00005007830
Gene Symbol: CACNB2A
1 Cross references
201 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSMMDG00005000498
Gene Symbol: CACNB3A
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).